Your browser doesn't support javascript.
loading
Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu, Di; Lu, Pan; Mi, Xue; Miao, Jinwei.
Afiliação
  • Wu D; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
  • Lu P; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
  • Mi X; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
  • Miao J; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China. miaojinweibjfc@126.com.
Arch Gynecol Obstet ; 297(3): 699-707, 2018 03.
Article em En | MEDLINE | ID: mdl-29327155

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cisplatino / Resistencia a Medicamentos Antineoplásicos / Fosfatidilinositol 3-Quinases / MicroRNAs / Carcinoma Epitelial do Ovário Limite: Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cisplatino / Resistencia a Medicamentos Antineoplásicos / Fosfatidilinositol 3-Quinases / MicroRNAs / Carcinoma Epitelial do Ovário Limite: Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article